Meeting
2021 ASCO Annual Meeting
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.
Authors
Vladislav Berdunov
PHMR Ltd, London, United Kingdom
Vladislav Berdunov , Steve Millen , Andrew Paramore , Sarah Reynia , Nina Fryer , Jane Griffin , Nadia Georges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 534)
DOI
10.1200/JCO.2021.39.15_suppl.534
Abstract #
534
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao
Poster
2019 ASCO Annual Meeting
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.
First Author: Nadia Harbeck
Poster
2018 ASCO Annual Meeting
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.
First Author: Wolfgang Janni